Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adam Baker

Dermatology Germantown, TN Medical Doctor

NPI 1316955578 CMS profile 105348

2120 Merchants Row, Suite 2, Germantown, TN 38138

Open in the dashboard

General payments

$6,980

463 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adam Baker of Germantown, TN is reported in the CMS Open Payments database as having received $6,980 across 463 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $607 32
2024 General $1,630 108
2023 General $1,336 78
2022 General $1,010 71
2021 General $923 59
2020 General $688 51
2019 General $786 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Baker
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Adam Baker were reported at $607. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Adam Baker Dermatology median Middle half National median
2019 $786 $454 $129–$1,240 $163
2020 $688 $235 $81–$756 $114
2021 $923 $377 $108–$1,108 $132
2022 $1,010 $514 $143–$1,391 $149
2023 $1,336 $607 $159–$1,674 $160
2024 $1,630 $751 $204–$1,903 $164
2025 $607 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,273 176 payments
  2. Janssen Biotech, Inc. $675 30 payments
  3. Novartis Pharmaceuticals Corporation $608 31 payments
  4. Pfizer Inc. $546 33 payments
  5. Galderma Laboratories, L.P. $363 48 payments
  6. Lilly USA, LLC $356 20 payments
  7. Sun Pharmaceutical Industries Inc. $307 19 payments
  8. Dermavant Sciences, Inc. $253 22 payments
  9. Genzyme Corporation $226 11 payments
  10. LEO Pharma Inc. $207 11 payments
  11. Other $1,168 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,645 459 payments
  2. Education $336 4 payments
Products named General payments · program years 2019–2025
  1. SKYRIZI $1,443 124 payments
  2. HUMIRA $942 58 payments
  3. TREMFYA $532 22 payments
  4. EUCRISA $396 26 payments
  5. DUPIXENT $372 15 payments
  6. COSENTYX $365 18 payments
  7. CIBINQO $346 19 payments
  8. TALTZ $319 18 payments
  9. SIMPONI ARIA $314 17 payments
  10. STELARA $314 17 payments
  11. Other $3,752 281 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

103

Median for Dermatology: 534

Drug cost

$3,912

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Hyclate Generic 16 $2,094
Fluocinolone Acetonide Generic 23 $1,069
Finasteride Generic 51 $428
Clobetasol Propionate Generic 13 $321

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $310
$310 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $188
$188 — —
VTAMA
  • Dermavant Sciences, Inc. $176
$176 — —
DUPIXENT
  • SANOFI-AVENTIS U.S. LLC $99
  • GENZYME CORPORATION $47
$146 — —
TALTZ
  • Lilly USA, LLC $108
$108 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

463 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record